CD38 and acute myeloid leukemia: A potential unique marker of LSCs is interleukin-3 receptor alpha chain (CD123) which has been shown to be highly expressed on leukemic but not normal CD34+/CD38− hematopoietic cells, with a negative impact on the outcome and prognosis in AML patients [8–10] (Table 1).